R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma — Stella

Home/Lymphadenopathy Retroperitoneal/

View on ClinicalTrials.gov

Recruiting

Back to Lymphadenopathy Retroperitoneal trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

Canada

Princess Margaret Cancer Centre, Toronto, Ontario

Key details

Sponsor

University Health Network, Toronto

Enrollment target

~25 participants

Started

February 2022

Primary completion

November 2030

Age range

18 Years and older

Sex

Male only

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.